Protocol Specific Research Support

CCSG用于协议特定研究支持(PSR)的资金用于NYUCI的开发 研究人员发起的早期阶段协议。NYUCI高度重视这类研究，因为它们 代表了NCI癌症中心计划最有希望的好处之一。应计至调查员启动 纽约大学的研究在上一个资助期翻了一番，这一类别现在占到了两个 所有应计项目的三分之一。2005年的38项研究中有23项是第一阶段、L/11阶段和试点方案 从而有可能有资格获得PSRS支持。使用严格的标准来分配这些资金，包括 PRMC分配的科学优先顺序，适当的疾病管理小组的建议 和/或CCSG科学计划，对此类资源的需求，以及研究将导致 随后经同行评审的资助或纳入合作小组或联盟的研究。这个 PSRS资金的最终分配是由临床癌症调查委员会做出的。

CCSG funds for Protocol Specific Research Support (PSRS) are used for development of NYUCI investigator-initiated early phase protocols. The NYUCI places a high priority on such studies since they represent one of the most promising benefits of the NCI Cancer Centers Program. Accrual to investigatorinitiated studies at NYUCI has doubled over the last funding period and this category now accounts for two thirds of all accruals. Twenty three of the 38 studies in 2005 were phase I, phase l/ll, and pilot protocols thereby potentially qualifying for PSRS support. Strict criteria are used to allocate these funds including scientific priority assigned by the PRMC, recommendation by the appropriate Disease Management Group and/or CCSG scientific program, need for such resources, and likelihood that the study will lead to subsequent peer-reviewed funding or incorporation into cooperative group or consortium studies. The ultimate decision for allocating PSRS funds is made by the Clinical Cancer Investigation Committee.